Although the role of ICIs in HER2-positive breast cancer remains unclear, many studies suggest that tumor immunogenicity plays an important role in treatment response and prognosis in HER2-positive breast cancer, as well as triple-negative breast cancer [34,35]. The gene discussed is ERBB2; the disease is breast carcinoma.